Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Topics Oct 01 | 2018UPDATED: Novo to Launch Connected Pens and New Connected Care Partnerships with Dexcom, Roche, and GlookoPurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Topics Sep 30 | 2018New H2H Tresiba vs. “Lantus” CGM Crossover Study (SWITCH PRO)Purchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Topics Sep 28 | 2018Novo To Layoff 250 US WorkersPurchase Blast
$599
Posted in: GLP-1RA, Topics Sep 27 | 2018New Sanofi Efpeglentatide vs. Trulicity Study InitiatedPurchase Blast
$599
Posted in: Glucagon, Topics Sep 27 | 2018Zealand Initiates Ph3 Dasiglucagon Pediatric Hypoglycemia StudyPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, SGLT2i, Topics Sep 26 | 2018HARMONY @ EASD: Why You, AZ, and LLY, Should CarePurchase Blast
$599
Posted in: Insulin Delivery, Topics Sep 25 | 2018Tandem to Pioneer iPump Regulatory Pathway; Shares Close to $50Purchase Blast
$599
Posted in: GLP-1RA, Topics Sep 25 | 2018Bydureon EU label to Include All-Cause Mortality Data from EXSCELPurchase Blast
$599
Posted in: SGLT2i, Topics Sep 24 | 2018DECLARE Hits on HF Endpoint but Not 3P-MACE; Bad News for CANVAS Review?Purchase Blast
$599
Posted in: GLP-1RA, Topics Sep 20 | 2018Oral Semaglutide Superior to Trulicity in Japanese Subjects (PIONEER 10)Purchase Blast
$599
Posted in: Bolus Insulin, Insulin Delivery, Topics Sep 19 | 2018Dance Biopharm Raises $24.5M for Inhaled Insulin DevelopmentPurchase Blast$599
Posted in: Glucagon, Topics Sep 18 | 2018Dasiglucagon Ph3 Meets Primary and Secondary EndpointsPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Insulin Delivery, Other, Topics Sep 18 | 2018Novo Cuts 400 Jobs in Denmark/China and Confirms Shift in R&D StrategyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Topics Sep 17 | 2018Oramed Oral GLP-1RA Receives IND ApprovalPurchase Blast
$599
Posted in: Other, Topics Sep 17 | 2018ViaCyte and CRISPR Therapeutics Collaborate for T1DM Stem Cell TherapyPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Topics Sep 17 | 2018Beta Bionics Raises $50M, but No Lilly InvestmentPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, Glucagon, Other, SGLT2i, Topics Sep 14 | 2018New Lilly Academic Collaboration to Help Compete with Novo/OxfordPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
